I was looking at the presentation slides for JPM, and I found slide 21 very interesting. This is the first time, that I'm aware of, that HALO has listed the potential market opportunity for SC Herceptin and SC MabThera. Adjusted for indications available for SC, and x-US and X-Japan, their potential market opportunity is $2.9B for SC Herceptin, and $2.9B for SC MabThera.
I also noticed that this is the first time that they have not included a slide showing how much money they currently have (i.e., funded through xx qtr. of xxxx). I guess the days of dilution are long gone.
Soho - I like your opinions - always have. I got some different takeaways from the preso. 1. Halo has pushed everything out - except Hyl for Type 1 Diabetes, and it's now Hyl alone - so no integrated pump at $500M --- which might be ok - would just need to see the numbers at as a Pre. 2. I think the Roche Opp has been clearly identified for years - as a percentage based on region - no info on adoption rate - which is what everyone is waiting for, and 3. The PEG Trial info has been pushed back - 2 mos ago we were talking about 'breakthrough', now we're talking about 202 ONLY being launched in q4 of 2014. I'm still long and strong, don't get me wrong.
Thanks. I appreciate the exchange.
1. I don't think it was ever intended to be an integrated pump (although Yale is working on the closed-loop). What is the $500M?
2. While the overall Roche opportunity may have been discernible for awhile, this is the first time that I have seen the company break it down so clearly. I think that is important for potential investors.
3. To me, PEG hasn't been pushed back. I never expected info this year, with the possible exception of an update on the 1b trial (I don't know if they reached a median OS yet for the high HA group. Perhaps we will get that info tomorrow). I think Frost made that clear. As far as breakthrough, I think they need to see the phase 2 results first. And personally, I would rather they make sure it works before they pile a ton of $ into trials in different indications. I think another factor is the companion diagnostic that they are working on. That will be a necessary component to trials in any other indication.